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One Sentence Summary: Flortaucipir binding in the brain is increased may years after a single 
traumatic brain injury, providing evidence that positron emission tomography can be used to 
identify tau pathology following head injury. 
 
  
Abstract: Traumatic brain injury (TBI) can trigger progressive neurodegeneration, with tau 
pathology seen years after a single significant TBI. There are no diagnostic tests to identify this 
type of post-traumatic pathology in vivo.  Here we use Flortaucipir positron emission 
tomography (PET) to investigate whether tau pathology is present many years after a single TBI. 
We relate PET results to CSF, MRI and cognitive measures of late neurodegeneration. Cerebral 
Flortaucipir binding was variable with many TBI patients showing increases in cortical and 
white matter regions. Overall, Flortaucipir binding was increased in the right occipital cortex in 
the TBI group when compared to healthy controls. High binding was associated with increased 
CSF tau and UCH-L1 levels, as well as increased MRI measures of axonal injury, a precursor of 
tau pathology. The results demonstrate that tau PET is a promsing approach to investigating 




Traumatic brain injury (TBI) can lead to chronic neurodegeneration and dementia in later 
life (1, 2). Deposition of hyperphosphorylated protein tau neurofibrillary tangles is a pathological 
hallmark of this neurodegenerative process (3, 4). Since the first observations in post-mortem 
examinations of brain of boxers (5), the pathological features and clinical correlations of tau 
neurofibrillary tangle deposition in chronic traumatic encephalopathy (CTE) following repetitive 
TBI have been increasingly well characterised (3, 6, 7). However, tau deposition also occurs 
following a single TBI, after which abundant and widely distributed neurofibrillary tangles have 
been found post-mortem in approximately one-third of TBI patients (8). As in Alzheimer’s 
Disease (AD), all six isoforms of tau (including both 3- and 4-repeat isoforms) are observed in 
post-TBI tauopathy (3, 4). However, the distribution of tau pathology after TBI follows a pattern 
distinct from that observed in AD, concentrating primarily in the- depths of sulci and at points of 
geometric inflection in the cerebral neocortex, while the medial temporal lobe is relatively spared 
in early disease (8, 3). Although the pathogenic role of TBI as a trigger for tau aggregation is not 
fully understood, traumatic axonal injury appears to directly lead to tau hyperphosphorylation (9, 
10). 
Flortaucipir ([18F]AV-1451, [18F]T807), a recently developed positron emission 
tomography (PET) radioligand for tau, enables the examination of tau pathology in vivo (11, 12). 
Flortaucipir demonstrated potent and specific non-displaceable binding to tau neurofibrillary 
tangles in post-mortem human brain tissue in AD (13–15). Flortaucipir is selective for tau, with 
no significant binding to β-amyloid, α-synuclein or TDP-43, although it also binds ‘off-target’ to 
neuromelanin- and melanin-containing cells (13). In vivo, Flortaucipir binding is increased in AD 
patients with a regional pattern in keeping with the clinical phenotype (16–18), cognitive profile 
(16, 17) and estimated Braak & Braak staging (19). In tau mutation carriers (MAPT gene) and in 
AD, the distribution of in vivo Flortaucipir binding and that of post-mortem tau pathology are 
strongly concordant (18, 20). Furthermore, in both typical AD and posterior cortical atrophy, 
Flortaucipir binding follows the pattern of regional atrophy as quantified by MRI (21, 22).  
The role of Flortaucipir in quantifying tau pathology and its distribution in long-term 
survivors of a single TBI has not been studied. A case report decribes a retired National Football 
League player exposed to repetitive TBI and manifesting progressive neuropsychiatric symptoms 
with increased Flortaucipir binding in bilateral cingulate, occipital, orbitofrontal and temporal 
cortices (23). The relationships of tau pathology to clinical outcome and biomarkers of 
neurodegeneration are also unclear. Of particular interest is the relationship between tau 
pathology and white matter microstructural changes related to traumatic axonal injury, as these 
will help to clarify the pathophysiological relationship between the initial injury and progressive 
neurodegeneration.  
Here we used Flortaucipir PET to study the distribution of tau pathology in individuals at 
least 18 years after a single moderate-severe TBI and in healthy controls.  Patients were 
primarily recruited from a patient cohort under follow-up at the University of Glasgow, who 
have previously been followed up longitudinally in terms of cognitive, wellbeing and disability 
outcomes (24, 25). We hypothesized that: i) Flortaucipir binding would be increased in a 
proportion of TBI patients many years after their injury; ii) Flortaucipir binding would correlate 
with levels of CSF tau and other CSF and blood biomarkers of neuronal damage and 
neurodegeneration; iii) Flortaucipir binding would be associated with the extent and distribution 
of diffuse axonal injury produced by the initial injury, quantified by diffusion MRI and voxel-
based morphometry (VBM); and iv) Flortaucipir binding is associated with poor long-term 





Participant demographic and clinical characteristics 
21 patients [7 female, 14 male; median age: 49 years (range: 29 to 72)] with a history of a 
single moderate-severe TBI were included in the study. Participants were examined at a median 
time of 32 years (range: 18 to 51 years) following their injury. TBI was caused by road traffic 
accidents in 18 participants (86%), assault in 2 (10%) and fall from a height in 1 patient (5%). 
Glasgow Outcome Scale – Extended (GOS-E) median score was 6 (range: 4 to 8) at the time of 
assessment. In 15 patients (71%) longitudinal clinical data were also available, including GOS-E 
and MMSE scores obtained at a median timepoint of 16 years (range: 9 to 19 years) after the 
injury and 17 years (range: 15 to 19 years) before the current clinical and imaging assessment. 
The demographic and clinical characteristics and ApoE genotype of individual TBI patients are 
presented in Table 1. Nineteen patients (90%) had focal lesions with a median volume of 1634 
voxels (range: 12 to 23118 voxels; Suppl. Fig. 1).  
 










(change) ApoE  
P1 56 Female RTA 35 5 (0) 22 (-2) ε3/ε3 
P2 39 Female RTA 28 5 (-1) 27 (-2) ε3/ε3 
P3 61 Female RTA 35 5 (-1) 28 (-2) ε3/ε3 
P4 39 Male RTA 32 4 (0) 28 (-1) ε3/ε4 
P5 57 Male RTA 35 8 (0) 30 (0) ε3/ε4 
P6 54 Female RTA 36 5 (-3) 27 (2) ε3/ε4 
P7 65 Male Fall 31 7 (0) 30 (2) ε3/ε4 
P8 29 Female RTA 18 7 (NA) 29 (NA) ε3/ε3 
P9 49 Male RTA 27 5 (NA) 28 (NA) ε2/ε3 
P10 48 Male RTA 37 6 (-2) 29 (-1) ε3/ε3 
P11 46 Female RTA 31 8 (0) 29 (0) ε3/ε3 
P12 44 Male RTA 29 6 (-1) 24 (-2) ε3/ε3 
P13 54 Male RTA 32 7 (0) 29 (NA) ε3/ε3 
P14 57 Male RTA 37 8 (0) 30 (3) ε3/ε3 
P15 54 Male RTA 34 5 (-1) 29 (2) ε3/ε4 
P16 38 Male RTA 19 8 (NA) 29 (NA) ε3/ε3 
P17 72 Male Assault 51 5 (NA) 27 (NA) ε3/ε3 
P18 40 Female RTA 31 5 (0) 23 (-6) ε3/ε4 
P19 43 Male RTA 35 8 (0) 30 (0) ε3/ε3 
P20 55 Male Assault 20 8 (NA) 30 (NA) ε3/ε4 
P21 43 Male RTA 20 5 (NA) 26 (NA) ε4/ε4 
Abbreviations: ApoE: apolipoprotein E genotype; GOS-E = Glasgow Outcome Scale Extended; MMSE = Mini-
Mental State Examination; NA = not available; RTA = road traffic accident; TBI = traumatic brain injury. 





Outcome measure TBI vs Healthy participants Disabled vs Good recovery TBI subgroups 
 TBI 
mean (+/- SD)  
Controls 
mean (+/- SD)  
W  P Disabled TBI 
subgroup 
mean (+/- SD)  
Good recovery TBI 
subgroup 
mean (+/- SD)  
W  P 
Age (years)  49.7 (10.3) 54.2 (12.1) 80 0.16 49.9 (10) 49.3 (11,2) 35 0.29 
Time since injury 
(years) 
 31.1 (7.6) - - - 32.9 (7.4) 28.7 (7.5) 66.5 0.39 
Education (years)  12.5 (3.6) 11.5 (2.8)  124.5 0.73 11.5 (3.2) 13.9 (3.8) 33.5 0.15 
Premorbid 
intelligence 
WTAR (scaled) 101.4 (16.4) 110.3 (10.8) 76.5 0.13 92.6 (16.1) 113.1 (6.8) 9.5 0.002 
Cognitive impairment MMSE (current) 26.5 (2.3) 29.5 (0.5) 4 <0.001 26.5 (2.3) 29.5 (0.5) 4 <0.001 
MMSE (change) -0.5 (2.3) - - - -1.3 (2.4) 1 (1.4) 7 0.041 
Logical reasoning WASI Matrix Reasoning  22.7 (8.2) 25.2 (7) 87 0.46 18.1 (7.3) 28.9 (4.4) 8.5  0.001 
Processing speed 
 
Trail Making Test A (s) 39.9 (20.6) 28.9 (14.4) 153 0.079 49.7 (22.9) 27.9 (7.6) 81 0.016 
Trail Making Test B (s) 106.8 (69.8) 57.4 (18.3) 158 0.049 140.8 (75.3) 65.2 (30.6) 81 0.016 
Stroop Combined Baseline (s) 50.8 (10.8) 41.1 (8.5) 175 0.017 52.7 (12.3) 48.2 (8.6) 67 0.38 
CRT RT (ms) 579 (121) 512 (103) 160.5 0.077 645 (115) 491 (53) 94 0.003 
Executive function Trail Making Test B-A (s) 66.9 (56) 28.5 (8.7) 145 0.15 91.1 (63) 37.3 (26.3) 79  0.028 
Stroop Inhibition-Switch(s) 93 (48.7) 65.3 (20.4) 164 0.056 116.4 (52.7) 61.9 (14.2) 100 <0.001 
Stroop Inhibition-Switch vs 
Baseline (s)  
71.4 (50.7) 51.8 (18.9) 145 0.25 94.6 (54.5) 40.42 (21.2) 96 0.002 
FrSBe-Executive; current 42.2 (8.2) 26.3 (5.7) 181.5 <0.001 46 (8.2) 37.1 (4.9) 89.5 0.012 
Apathy  LARS  -21.5 (10.1) -27.2 (6.3) 134 0.14 -17.2 (10.7) -27.9 (4.5) 82 0.009 
FrSBe-Apathy; current 31.9 (9.6) 21 (5.1) 157.5 0.005 34.3 (10.5) 28.8 (7.8) 71 0.24 
Impulsivity / BIS  66.6 (15.8) 58.1 (6.9) 118.5 0.29 72.9 (15) 57.9 (13.2) 75 0.039 
Disinhibition 
FrSBe-Disinhibition; current 33.5 (10.3) 24.3 (5.3) 143.5  0.028 36.1 (11.5) 30.1 (7.7) 70.5 0.25 
Verbal memory PT Immediate Recall  18.3 (8.7) 19.8 (8.2) 102 0.61 16.4 (9.2) 20.4 (7.8) 39.5 0.32 
PT Delayed Recall 6.4 (3.8) 7.3 (3.6) 100.5 0.56 5.6 (3.9) 7.6 (3.5) 38.5 0.28 
HVLT Immediate Recall  21.2 (5.3) 25.5 (4.7) 63 0.038 19.4 (4.9) 23.7 (5) 25.5 0.046 
HVLT Delayed Recall 6.3 (3.6) 8.8 (2.5) 65.5 0.048 5.3 (3.9) 7.7 (2.7) 34 0.16 
HVLT RDI 9.2 (2.4) 9.9 (2) 97 0.47 8.7 (2.8) 10 (1.5) 40 0.33 
Visual memory Paired Associates Learning (z-
score) 
-1.47 (0.81) -0.73 (0.92) 66 0.043 -1.79 (0.77) -1.03 (0.69) 25.5 0.036 
BVMT Immediate Recall  16.2 (8.3) 21.7 (5.5) 63 0.039 10.9 (3.7) 23.3 (7.5) 7 <0.001 
BVMT Delayed Recall 6.8 (3.7) 9.5 (1.4) 64.5 0.044 4.7 (3.1) 9.6 (2.4) 12 0.003 
BVMT RDI 4.9 (1.3) 5.9 (0.3) 67.5 0.026 4.3 (1.4) 5.9 (0.3) 16 0.004 
Visuospatial ability Feature match test (z-score) -1.46 (0.74) -1.19 (0.92) 94.5 0.42 -1.88 (0.69) -0.89 (0.31) 6  <0.001 
Mood disturbance HADS-Anxiety 8 (6) 3.9 (3.8) 161.5 0.069 9.9 (5.6) 5.3 (5.7) 80.5 0.063 
HADS-Depression 4.5 (4.7) 1.9 (2.5) 156 0.11 6.4 (5.1) 1.8 (2.4) 86.5 0.022 
Abbreviations: BIS = Barratt Impulsivity Scale; BVMT = Brief Visuospatial Memory Test; CRT = Choice reaction time; PT = People’s Test; FrSBe = Frontal 
Systems Behavior Scale; HADS = Hospital Anxiety and Depression Score; HVLT = Hopkins Verbal Learning Test; LARS = Lille Apathy Rating Scale; MMSE 
= Mini-mental State Examination; ms = milliseconds; RDI = Recognition Discrimination Index; RT = Reaction time; s = seconds; SD = Standard deviation; 
WASI = Wechsler Abbreviated Scale for Intelligence; WTAR = Wechsler Test of Adult Reading. 
Table 2: Demographic and neuropsychological comparisons between TBI patient and healthy control groups, as well as between disabled TBI and good 
recovery TBI subgroups. Independent sample Mann-Whitney-Wilcoxon test W and P-values (P<0.05 in bold) are provided for comparisons between groups 
and subgroups. 
 
11 healthy controls [5 female, 6 male; median age: 57 years (range: 29 to 72)] 
of similar educational background and estimated premorbid intelligence to the TBI 
participants were also examined. The demographic characteristics of the TBI and 
control groups are presented in Table 2.  
We divided TBI participants into a good recovery and a disabled subgroup 
based on their Glasgow Outcome Scale – Extended scores (disabled subgroup: GOS-
E≤6; good recovery subgroup: GOSE>6). Twelve participants [5 female, 7 male; 
median age: 48.5 years (range: 39 to 72)] with a median GOS-E of 5 (range: 4 to 6) 
were included in the disabled subgroup and 9 TBI participants [2 female, 7 male; 
median age: 54 years (range: 29 to 65)] with a median GOS-E of 8 (range: 7 to 8) 
were included in the good recovery subgroup. Longitudinal clinical data were 
available for 9 patients (75%) in the disabled and 6 patients (67%) in the good 
recovery group. The demographic characteristics of these subgroups are presented in 
Table 2. 
 
Neuropsychological performance  
When compared to healthy controls, TBI participants manifested impairments 
on multiple cognitive domains including processing speed, executive function, 
motivation, inhibition, verbal and visual memory (Table 2), in a neuropsychological 
profile typical of TBI. The good recovery TBI subgroup performed better than the 
disabled subgroup on several cognitive domains including logical reasoning, 
processing speed, executive function, motivation, inhibition, verbal memory, visual 
memory and mood assessment (Table 2). As shown in Table 2, there was evidence of 
cognitive decline on longitudinal assessment (average -1.3 point on MMSE) in the 
disabled TBI subgroup while the good outcome TBI subgroup showed improvement 
of cognitive performance over time (average 1 point on MMSE), with longitudinal 




Flortaucipir binding in individual TBI patients  
To obtain a quantitative assesment of Flortaucipir binding and its distribution 
in the brain in individual TBI patients, voxelwise z-scores of MNI registered 
Flortaucipir binding potential (BPND) images were derived for each patient versus the 
healthy control group. This approach allows areas of increased binding to be 
identified in the individual, relative to variations in binding seen in healthy subjects. 
As illustrated in Fig. 1, several TBI participants had increased Flortaucipir binding in 
a patchy cortical and subcortical distribution (Fig. 1: P1 to P8 and P10). In contrast, 
other TBI participants had similar Flortaucipir BPND to that of healthy controls (Fig. 




Fig. 1: Flortaucipir BPND z-score maps for each TBI individual compared voxelwise to 
healthy controls. TBI participants are presented in descending order of number of voxels 
with Flortaucipir BPND z>1.645 (see Figure 2). Axial images are displayed in radiological 
convention at MNI coordinate 55. Patchy cortical and subcortical increase in tracer uptake is 
observed in some patients, most consistently in the lateral occipital cortex (P1 to P8 and 
P10), while other patients show similar BPND values as controls (P17 to P21). The 
corresponding clinical characteristics are presented in Table 1. 
 
The number of voxels with high BPND (z>1.645; corresponding to one-tailed 
P<0.05) was used to measure the spatial extent of increased Flortaucipir signal in 
individual patients (Fig. 2). TBI participants had a median 841 voxels above 
threshold (range: 0 to 15809). For comparison, voxelwise z-scores were also derived 
for each healthy control versus the rest of the control group. In controls, the median 
number of voxels above threshold was 4 (range: 0 to 253; Fig. 2).  
Eight TBI participants (38%) had >2000 voxels (equivalent to 16 cm3 of brain 
volume) above threshold indicating spatially extensive Flortaucipir signal increase, 
while a further 7 (33%) showed increased signal of more spatially limited extent 
(254-1999 voxels, Fig. 2). The remaining 6 TBI patients (29%) had less than 253 
voxels above threshold, falling within the range of the healthy control group. There 
was no difference in the spatial extent of high Flortaucipir signal when comparing 
between disabled and good functional outcome subgroups (Mann-Whitney-Wilcoxon 
W=68.5, P=0.32). 
 
Fig. 2: Spatial extent of increased Flortaucipir signal in TBI. Spatial extent of Flortaucipir 
binding is expressed as the number of voxels with Flortaucipir BPND z>1.645 for each TBI 
patient compared to the healthy control group. The dotted line represents the number of 
voxels above threshold in the healthy control subject with the maximum number of voxels 
above that threshold (compared to the rest of the controls). The inset figure shows the number 
of voxels above threshold (in logarithmic scale) in TBI and healthy controls.  
 
Reduced Flortaucipir binding within focal lesions in TBI 
Flortaucipir binding within focal lesions was significantly reduced when 
compared to non-lesioned cerebral areas (Wilcoxon signed-rank V=22, P=0.002). 
Areas of markedly reduced Flortaucipir uptake (in black) in Fig. 2 correspond to focal 
lesions in individual patients (cf Suppl. Fig. 1).  
 
Increased Flortaucipir binding in the TBI patient group vs. healthy controls 
Flortaucipir BPND was next compared between TBI and healthy control 
groups, excluding lesioned areas and also the striatum where off-target binding is 
observed with this tracer (Suppl. Fig. 1). Flortaucipir binding was significantly higher 
in TBI participants than in healthy controls in the right lateral occipital cortex (Fig. 3 
inset; P<0.05, adjusted for multiple comparisons). There was no significant difference 
in Flortaucipir binding when comparing between the disabled (GOS-E≤6) and good 
outcome (GOS-E>6) TBI subgroups. When each of the TBI subgroups was 
independently compared to healthy controls, significantly increased Flortaucipir 
binding was found in both TBI subgroups,  in the same right lateral occipital area 
(Fig. 3). There were no areas of significantly decreased binding in the TBI group or 
subgroups compared to healthy controls. 
 
 
Fig. 3: Increased Flortaucipir BPND in TBI compared to healthy controls. Voxels with 
increased Flortaucipir uptake in TBI at P<0.05, not adjusted for multiple comparisons, are 
shown on axial slices for illustration. Flortaucipir binding was increased in TBI in a small 
cluster of voxels in the right parietal cortex (inset, P<0.05, corrected for multiple 
comparisons).  
 
Cortical Flortaucipir correlates with CSF tau and UCH-L1 in TBI 
Next, CSF and serum biomarkers of neurodegeneration and neuronal damage, 
including total tau, UCH-L1, NFL, GFAP and S100 were assessed in TBI and healthy 
controls and their relationship with Flortaucipir uptake was examined. CSF data was 
available from 19 TBI participants and 10 healthy controls. In TBI, increased CSF tau 
was significantly correlated with increased Flortaucipir BPND in the cerebral cortical 
grey matter (Spearman ρ=0.53, P=0.023; Fig. 4A). CSF tau did not correlate with 
Flortaucipir uptake in healthy controls. Plasma tau levels did not show significant 
correlations with Flortaucipir uptake in either TBI or healthy controls. Tau levels in 
CSF and plasma were not different between TBI and healthy control groups.  
UCH-L1 in the CSF in TBI participants also positively correlated with 
Flortaucipir BPND in the grey matter (Spearman ρ=0.52, P=0.023; Fig. 4B), but not in 
the white matter. There was no significant association between plasma UCH-L1 and 
Flortaucipir uptake in TBI. In healthy controls, there were no significant associations 
between Flortaucipir uptake and UCH-L1 in the CSF or plasma. There was no 
statistically significant difference between TBI and control groups in UCH-L1 levels. 
There were also no statistically significant associations between Flortaucipir BPND 
and NFL, GFAP or S100 in TBI or healthy controls and no significant dfference 




Fig. 4: Flortaucipir and CSF biomarkers in TBI. Flortaucipir BPND in the cerebral grey 
matter is positively correlated with tau and UCH-L1 CSF levels in TBI participants.  
 
Flortaucipir spatial extent correlates with white matter damage in TBI 
Next, we investigated the relationship between Flortaucipir binding and 
structural brain injury produced by TBI (26). White matter integrity measured by 
fractional anisotropy (FA) was significantly reduced in TBI when compared to 
healthy controls (Mann-Whitney-Wilcoxon W=44, P=0.004), in keeping with the 
presence of traumatic axonal injury (TAI) in TBI. Tissue density measured by voxel 
based morphometry (VBM) was also significantly reduced in the non-lesioned white 
matter in TBI (Mann-Whitney-Wilcoxon W=61, P=0.031). Tissue density in the non-
lesioned grey matter was not significantly different between TBI and healthy control 
groups (W=113, P=0.94).  
The spatial extent of Flortaucipir binding (number of voxels with BPND 
z>1.645) correlated with the degree of white matter damage see in TBI patients. The 
number of voxels showing increased Flortaucipir binding was negatively correlated 
with both average FA (Spearman ρ=-0.48, P=0.027) and average white matter density 
(Spearman ρ=-0.46, P=0.037), in keeping with a relationship between more tau 
pathology in the cortex with microstructural white matter disruption. There was no 
relationship between Flortaucipir binding and gray matter tissue density. 
 
White matter damage seen in areas of increased Flortaucipir binding 
We next examined whether greater white matter pathology was seen in areas 
of increased Flortaucipir binding. As the location of post-traumatic damage varies 
from patient to patient, we defined areas of high and low Flortaucipir signal (BPND z 
> or < 1.645) in each patient. Within the white matter, eight patients showed low 
Flortaucipir signal within the white matter they were excluded from these analyses. 
Significantly lower FA (Figure 5A-B; Wilcoxon signed-rank V=19, P=0.018) and 
white matter density (Figure 5C-D; Wilcoxon signed-rank V=17, P=0.025) was seen 
in areas of high Flortaucipir binding compared to areas where binding was not 
increased, demonstrating realtively high Flortaucipir binding in areas of post-
traumatic white matter damage. The corresponding VBM analysis for grey matter 
density did not reveal significant differences in  gray matter density in areas of high 
or normal Flortaucipir binding.  
 
Fig. 5: Co-localisation of increased white matter Flortaucipir BPND with white matter 
microstructural changes in TBI. Skeletonized FA (A) and white matter density (B), 
standardized against controls, were compared within subject between areas of increased 
Flortaucipir binding (in red) and areas where binding was not increased (in green). A 
representative axial slice for each patient shows the spatial distribution of the white matter 
areas compared and images are presented in order of greatest to smallest effect size (greatest 
decrease in FA or white matter density z-score in high Flortaucipir areas shown top left). 
Both FA z-scores (B) and white matter density z-scores (D) are lower within areas of 
increased Flortaucipir binding, defined as BPND Z > 1.645. 
 
Cortical Flortaucipir binding and white matter microstructural damage 
Next, we examined whether Flortaucipir BPND within the right lateral occipital 
cortical area where Flortaucipir signal was significantly increased in TBI vs controls 
(Fig. 3) was associated with white matter tract FA. Increased right lateral occipital 
Flortaucipir binding was associated with reduced FA in remote white matter regions, 
including association, comissural and projection tracts in the ipsilateral and 
contralateral hemisphere (Fig. 6A&B and Supplementary Table S1). Correlations 
were observed in the genu and body of the corpus callosum, as well as in several 
association tracts within the ipsilateral (right) hemisphere, including the cingulum 
bundle, inferior longitudinal fasciculus, uncinate fasciculus and anterior thalamic 
radiation, but not in the contralateral hemisphere. Higher cortical Flortaucipir BPND 
was associated with significantly reduced tissue density in remote white matter 
regions including the corpus callosum and right prefrontal white matter (Fig. 6C). A 
similar analysis for grey matter density did not show any significant association 
between Flortaucipir BPND within the lateral occipital cluster and cerebral cortical 
grey matter density. 
 
Fig. 6: Increased cortical Flortaucipir binding in the right lateral occipital area is 
associated with microstructural white matter damage in TBI. A) Increased Flortaucipir 
BPND in the right lateral occipital cortex in TBI patients was associated with reduced 
diffusion MRI-derived fractional anisotropy (FA) in remote white matter tracts (upper panel), 
partly overlapping with white matter tracts of reduced FA in TBI when compared to controls 
(lower panel). B) Flortaucipir BPND in the right lateral occipital cortex in TBI patients 
correlated negatively with average skeletonized FA within the genu and body of the corpus 
callosum as well as within the cingulum bundle, inferior longitudinal fasciculus, anterior 
thalamic radiation and uncinate fasciculus in the right hemisphere. Correlation coefficients 
and P-values presented in Table 3. C) Increased Flortaucipir BPND in the right lateral occipital 
cortex in TBI patients is associated with reduced voxel-based morphometry-derived white 
matter density in the corpus callosum and right prefrontal area (upper panel). This 
distribution partly overlaps with areas of white matter atrophy in TBI when compared to 
controls (lower panel). Results presented in radiological convention, color maps represent P 
values <0.05 adjusted for multiple comparisons. 
 
Flortaucipir PET and neuropsychological measures in TBI 
There were no significant correlations between average Flortaucipir BPND in 
the cerebral grey or white matter and any clinical or neuropsychological measures in 
the TBI participants (all P>0.05, false discovery rate-adjusted, Supplementary Table 
S2). Furthermore, there was no statistically significant correlation between the spatial 
extent of high Flortaucipir signal in TBI patients (number of voxels above BPND 
z>1.645) and any clinical or neuropsychological measures in TBI (Table S1; all 
P>0.05, false discovery rate-adjusted). 
 
Interaction between ApoE genotype and age on Flortaucipir cortical uptake 
There were no differences between TBI participants with at least one ApoE ε4 
allele and those without an ApoE ε4 allele in Flortaucipir BPND in either grey or white 
matter or in Flortaucipir spatial extent (Mann-Whitney-Wilcoxon: W=38, P=0.34; 
W=48, P=0.80; W=44, P=0.60, respectively). Possible interactions between ApoE 
status (ε4 vs other) and age on Flortaucipir uptake was examined using linear 
regression.  There was a signficant interaction between ApoE genotype and age on 
Flortaucipir BPND in the cortical grey matter (χ
2 test, P=0.033), with older individuals 
carrying at least one ApoE ε4 allele showing higher Flortaucipir cortical uptake. 
There were no interactions between age and ApoE status on Flortaucipir white matter 
uptake and on Flortaucipir spatial extent were not statistically significant (P=0.059; 
P=0.78, respectively).   
 
Off target striatal binding is similar in TBI and healthy controls 
In keeping with the known off-target binding of Flortaucipir to neuromelanin 
(13) Flortaucipir BPND was increased in the striatum in both TBI participants and in 
healthy controls when compared to the rest of the cerebral white and grey matter, 
excluding focal lesions (Wilcoxon signed-rank patients: V=214, P=0.0002; controls: 
V=66, P=0.001;). However, Flortaucipir BPND within the striatum was not 
significantly different between TBI participants and healthy controls (Mann-Whitney-




Hyperphosphorylated tau deposition is a key pathological feature of 
neurodegeneration triggered by traumatic brain injury (TBI) (3, 4). Patients are at 
increased risk of Alzheimer’s disease (AD) and chronic traumatic encephalopathy 
(CTE) after TBI, both  characterised by the accumulation of tau pathology. Positron 
emmission tomography (PET) ligands have recently been developed that specifically 
bind hyperphosophorylated tau , enabling the detection of tau pathology in vivo. We 
used Flortaucipir PET to investigate tau pathology in a well-characterized cohort of 
individuals who were examined many years after a single moderate-severe TBI (24, 
25). As predicted, there was considerable variability in the extent of Flortaucipir 
binding across TBI patients. Broadly, a third of patients showed extensive increases 
in cerebral Flortaucipir binding, a third showed more limited increases and a third 
showed no abnormality.  
Flortaucipir binds to neurofibrillary tangles containing abnormal tau in post-
mortem human brain tissue in AD (13–15). A lack of specificity has been a 
significant issue with previous PET tau ligands (27), but Flortaucipir is more 
selective and does not show significant β-amyloid, α-synuclein or TDP-43 binding. 
‘Off-target’ binding is present for neuromelanin- and melanin-containing cells, which 
leads to signal appearing within subcortical structures such as the striatum (13). 
Flortaucipir has been validated for the study of tau pathology in AD patients, showing 
binding that correlates with clinical phenotype (16–18), cognitive profile (16, 17) and 
estimated Braak & Braak staging (19). Tau pathology seen after TBI appears to be 
similar to AD, with all six isoforms of tau (including both 3- and 4-repeat isoforms) 
observed (3, 4). As a result, Flortaucipir is expected to bind tau pathology seen after 
TBI in a similar way to AD, albeit with a distinct spatial patern (3). 
The pattern of Flortaucipir binding potentially provides diagnostic 
information about the type of post-traumatic neurodegeneration. Tau pathology seen 
after TBI often has a distinct distribution from AD. In cases of CTE, tau pathology is 
concentrated in depths of cortical sulci (3, 6) and can be widely distributed in cortical 
areas following single TBI (8). In line with these pathological findings a number of 
our patients showed extensive Flortaucipir binding in cortical areas as well as in parts 
of the white matter. The spatial pattern of Flortaucipir binding would be atypical for 
AD (28) but is more in keeping with CTE (3, 4). It is also compatible with the 
spatially extensive tau neurofibrillary tangle pathology seen in approximately one-
third of patients studied several years after a single TBI (8).  
The relationship between tau pathology and Flortaucipir binding is supported 
by our cerebrospinal fluid (CSF) results. CSF tau is raised in incipient Alzheimer 
disease (29) and other tauopathies (30) and provides a diagnostic biomarker for AD 
(31). CSF tau increases in the days after TBI, generally falling to normal levels 8-12 
weeks after the injury (32, 33). To our knowledge, our study is the first to examine 
CSF tau several years after moderate-severe TBI. CSF tau was not increased across 
the TBI group, but there was significant variablity in levels within the group. The 
variability in cortical Flortaucipir binding correlated with CSF tau. Increased levels of 
binding were associated with increased CSF tau levels, supporting the the conclusion 
that increased Flortaucipir binding is indicative of the presence of cortical tau 
pathology. We also observed a positive correlation between CSF UCH-L1 levels and 
cortical Flortaucipir uptake. In the acute phase, UCH-L1 provides a biomarker 
indicating the presence of neuronal injury following TBI (34). It is abundant in 
cerebral neurons and is an important component of the ubiquitin-proteasome system, 
(35). Dysfunction of UCH-L1 is implicated in a number of neurodegenerative 
diseases (36, 37) and UCH-L1 is found within misfolded protein aggregates, 
including neurofibrillary tangles (38). UCH-L1 CSF levels are elevated in patients 
with Alzheimer disease (39) and our results suggest that the link between TBI and 
dysfunction in the ubiquitin-proteasome system warrants further investigation.  
We also showed a relationship between Flortaucipir binding and traumatic 
axonal injury (TAI), indicated by diffusion tensor imaging and white matter atrophy. 
Increased Flortaucipir binding was associated with the presence of TAI. This is in 
keeping with a causative role for TAI in the pathophysiology of post-traumatic tau 
pathology. Mechanical forces exerted at the time of head injuries are thought to 
disrupt axonal organization producing damage to microtubule structure and 
associated axonal tau (4). This damage may lead to  hyperphosphorylation of tau, 
misfolding, and neurofibrillary tangle formation, which eventually causes 
neurodegeneration (9, 10, 40). Mechanical forces are maximal in points of geometric 
inflection such as the base of cortical sulci (41), where tau pathtology is seen in CTE.  
In AD, increased Flortaucipir binding is greater in cortical regions that show 
atrophy (21, 22). We observed a slightly different relationship following TBI. White 
matter Flortaucipir binding was increasd in areas that also showed reduced fractional 
anisotropy and atrophy. This suggests that tau pathology was more marked in areas of 
TAI. In addition, cortical Flortaucipir binding also correlated with the extent of TAI 
within the white matter. For example, Flortaucipir binding in the right lateral occipital 
cortex, the most consistent area of increase, was correlated with reduced fractional 
anisotropy - in keeping with TAI -  in the inferior longitudinal fasciculus – a tract 
directly connected to that cortical area. This relationship might be explained by slow 
Wallerian degeneration that follows the initial injury and leads to the accumulation of 
tau pathology in connected cortical regions. Alternatively, prion-like spread of tau-
pathology might over time  result in the cortical accumulation of tau-pathology in 
regions that are connected to white matter regions initially damage by TAI (42, 43). 
We have previously reported a similar relationship between cortical amyloid 
pathology measured using [11C]-PiB PET and the degree of TAI in connected tracts 
(44), suggesting that the structure of the connectome may influence the location of 
post-traumatic tau and amyloid pathology in similar ways.  
Genetic factors are likely to partly explain the variability in neurodegenerative 
trajectory following TBI. ApoE ε4, the strongest risk factor for sporadic AD, is 
associated with increased β-amyloid and tau pathology (45). Carrying an ApoE ε4 
allele is also associated with poor functional outcome following TBI (46). ApoE ε4 
may act synergistically with TBI to elevate the risk of neurodegeneration (47, 48), so 
we tested the relationship between ApoE status and Flortaucipir binding. Flortaucipir 
binding was not increased in ApoE ε4 carriers. However ApoE interacted with age, 
with cortical Flortaucipir binding increasing with age when TBI patients had at least 
one ε4 allele. In a larger prospective TBI cohort of clinical outcome after TBI, which 
included some of the participants later recruited to our study, Teasdale and colleagues 
also showed an interaction between age and ApoE genotype at 6 months post-TBI, 
with less favourable clinical outcome found in younger ApoE ε4 carriers (25). These 
results suggest that ApoE ε4 may have a distinct interaction with age depending on 
whether early clinical or late neurodegenerative associations are being examined. 
Larger longitudinal studies will be necessary to clarify these relationships. 
Our study has a number of limitations, which should be considered. Firstly, 
the relatively small sample size is likely to have limited our ability to detect 
associations between Flortaucipir binding and clinical outcomes. We performed a 
planned comparison of Flortaucipir binding in good and poor outcome subgroups and 
found no difference in Flortaucipir binding, although both sub-groups showed 
increased levels of binding. The absence of a clinical effect should be interpreted with 
caution as our study is unlikely to have been adequately powered for these outcomes. 
In AD, Flortaucipir uptake was associated with poorer performance in various 
cognitive domains in regionally specific patterns (16), supporting the hypothesis that  
a similar relationship may be present following TBI. However, the situation is likely 
to be more complex following TBI as the influence of the initial injury on cognitive 
state will confound progressive neurodegenerative effects, meaning that larger sample 
sizes will be necessary to clarify the relationship between tau pathology and post-
traumatic cognitive impairment. Secondly, a minority of subjects were missing 
longitudinal neuropsychological or CSF data, which will have reduced statistical 
power with respect to these measures. Thirdly, as previously reported (13–15, 18, 20, 
49), Flortaucipir binding shows off-target binding to neuromelanin containing cells, 
which is particularly apparent in the striatum (13, 14). Off-target binding, albeit to 
lesser extent, has also been reported in areas of acute parenchymal and subarachnoid 
haemorrhage, but not in areas showing superficial siderosis due to chronic 
haemorrhage (13). This is unlikely to be a major confound in our study as there were 
no acute haemorrhagic lesions in our participants and we observed reduced binding 
within focal lesions. The off-target Flortaucipir binding may have limited our ability 
to detect underlying striatal tau pathology due to decreased signal to noise ratio in this 
region, although this will not have influenced the main cortical and white matter 
results we report. Finally, there may be concerns about the effect of brain atrophy or 
reduced tissue density on our PET results. We employed stringent measures to 
minimise the effects of atrophy during pre-processing. Moreover, the relationship 
between increased Flortaucipir binding and reduced white matter tissue density is 
unlikely to be artifactual, as non-specific Flortaucipir binding is expected to be 
reduced within areas of reduced tissue density, increasing the probabilty of false-
negative, not false-positive results.  
In summary, we show that Flortaucipir binding is increased many years after a 
single significant TBI. Increased binding was associated with CSF indicators of 
neurodegeneration, including tau levels, as well as the presence of TAI that may 
provide the initial trigger to its accumulation. The ability to detect tau pathology in 
vivo following TBI has major potential implications for diagnosis and prognostication 
of clinical outcomes after TBI. It is also likely to assist in patient selection and 
stratification for future treatment trials targeting tau.  
  
  
Materials and Methods 
Study design and participants 
Individuals were recruited with a history of a single moderate-severe TBI 
(according to Mayo classification (50)) at least 18 years prior to recruitment, and no 
prior significant neurological or psychiatric illness, or contraindication to PET or 
MRI. TBI participants were primarily recruited from a patient cohort under follow-up 
at the Institute of Health and Wellbeing, Head Injury Research Group, University of 
Glasgow, UK. These individuals have been followed up longitudinally in terms of 
cognitive, wellbeing and disability outcomes (24, 25). Additional TBI patients were 
recruited from the specialist multidisciplinary TBI clinic at Imperial College 
Healthcare NHS Trust, London, UK. Patients were divided into two subgroups based 
on functional outcome. Poor functional outcome was defined as a GOS-E score of 6 
or less (moderate-severe disability) at the time of assessment and those with GOS-E 
greater than 6 as good outcome. Healthy volunteers of similar age and socioeconomic 
background as the TBI participants were also recruited. The study was approved by 
the Westminster Research Ethics Committee and the Administration of Radioactive 
Substances Advisory Committee. All participants gave written informed consent. 
 
Procedures 
All participants were administered an IV bolus of Flortaucipir (also known as 
[18F]AV-1451 and [18F]T807), average dose 250 MBq and dynamic PET scans were 
acquired over 90 minutes. Flortaucipir was supplied by Avid Radiopharmaceuticals, a 
wholly owned subsidiary of Eli Lilly and Company and PET image acquisition was 
carried out at Imanova Centre for Imaging Sciences. All participants also underwent 
structural 3T MRI, including volumetric T1 and diffusion tensor imaging (DTI). 
Diffusion-weighted images were acquired along 64 non-collinear directions with 
b=1000s/mm2 and four averages with b=0s/mm2, with TE/TR 103/9,500ms, 64 
contiguous slices, FoV 256 mm, and voxel size 2×2×2 mm3.  
TBI participants and healthy controls took part in neuropsychological 
assessment focusing on cognitive domains often impaired after TBI (Table 2) (44, 
51). The Wechsler Test of Adult Reading (WTAR) estimated pre-morbid 
intelligence; the Wechsler Abbreviated Scale of Intelligence (WASI) Matrix 
Reasoning subtest assessed non-verbal reasoning; a tablet computer-based left/right 
choice-reaction task (CRT) measured processing speed (median reaction time (RT) 
on correct trials); complex processing speed and executive function was assessed 
with the Colour-Word Interference (Stroop) subtests from the Delis-Kaplan 
Executive Function System (inhibition and cognitive flexibility) and the Trail Making 
Test (TMT) (set maintenance and set shifting); a tablet computer-based paired 
associates learning (PAL) test assessed associative working memory; the People Test 
from the Doors and People Test assessed episodic memory; the Hopkins Verbal 
Learning Test (HVLT) assessed verbal immediate and delayed recall; visuospatial 
immediate and delayed recall were assessed using the Brief Visuospatial Memory 
Test (BVMT); complex visual perception was assessed using the tablet computer-
based Feature Match test. Participants also completed a Mini-Mental State 
Examination (MMSE).  
TBI and control participants had venous blood and cerebrospinal fluid (CSF) 
sampling. Clinical assessment, blood and CSF sample acquisition were carried out at 
the NIHR/Welcome Trust Imperial Clinical Research Facility.  
 
Biomarker and genetic analyses 
Microtubule-associated tau concentration was measured in plasma and CSF 
using the Human Total Tau kit (Quanterix, Boston, MA) with the Simoa HD-1 
Analyzer (Quanterix, Boston, MA). Briefly, samples, magnetic beads coated with 
Tau5 monoclonal capture antibody, and HT7 & BT2 monoclonal biotinylated 
detector antibodies were combined. Antibody epitopes in the mid-region of tau make 
the assay sensitive to normal and phosphorylated tau, including most of the known 
protein isoforms. 
Additionally, four biomarkers of axonal damage and neuronal degeneration 
(52) were mesured in plasma and CSF both in TBI and healthy controls using the 
Simoa Human Neurology 4-Plex Aassay (N4PA; Quanterix): ubiquitin carboxy-
terminal hydrolase L1 (UCH-L1), neurofilament light (NFL), glial fibrillary acidic 
protein (GFAP), and protein S100.  
Apolipoprotein E (ApoE) genotyping was performed on peripheral blood. 
DNA was extracted using the Qiagen QIAamp DNA blood mini kit. Genotyping of 
the c.388T>C p (SNP.rs429358) and the c.526C>T (SNP.rs7412) of the ApoE gene 
was performed using a TaqMan Allelic Discrimination assay.  
 
PET image processing 
Image preprocessing and model fitting of the Flortaucipir PET data was 
performed using the Molecular Imaging and Kinetic Analysis Toolbox (MIAKAT™, 
www.miakat.org). Motion correction of the dynamic PET images was performed with 
frame-by-frame correction using rigid body registration to a reference frame. The 
motion-corrected PET images were then registered to the individual’s T1 MRI image 
with a rigid-body registration resulting in a motion-corrected dynamic PET image in 
individual T1 space.  
The dynamic PET data was analysed using the simplified reference tissue 
model (SRTM) (53, 54). Cerebellar grey matter was chosen as the reference tissue, 
based on post-mortem studies in chronic traumatic encephalopathy which 
demonstrated relative sparing from tau pathology in that region (3, 7). The reference 
region was defined as follows. Structural MR images were segmented using the 
unified segmentation algorithm in SPM12 (55) to produce grey matter probability 
maps. Voxels exceeding a grey matter tissue probability of at least 0.9 were 
considered to be grey matter, to ensure only voxels corresponding to healthy grey 
matter were included in the reference region. The grey matter and white matter 
probability maps were subsequently used to create DARTEL (56) flow fields from 
subject space to MNI152 space. The inverse mappings of these flow fields were 
applied to the CIC atlas (57) to produce an atlas image in each individuals’ MR 
structural T1 space. The grey matter cerebellum reference region was defined as the 
intersection of the grey matter voxels (tissue probability of 0.9 or greater) and the 
voxels in the cerebellum ROI in the subject space atlas.  
Time activity curves (TAC) were generated for the reference region defined 
for each subject by plotting the mean intensity of the voxels in the reference region 
for each frame. Using this TAC as reference, SRTM was fitted at the voxel level to 
generate parametric images of Flortaucipir non-displaceable binding potential 
(BPND). Flortaucipir BPND parametric images were normalised to MNI152 space 
using the previously derived DARTEL flow fields from subject space to MNI152 
space. The flow fields were applied to the BPND parametric images without 
modulation using a 8mm full width at half maximum (FWHM) Gaussian smoothing 
kernel.  
To obtain a quantitative spatial measure of Flortaucipir binding in each 
individual patient as compared to healthy controls, voxelwise z-scores of MNI 
registered BPND images were derived for each patient versus the healthy control 
group. The spatially normalised BPND images were used to create a z-score image for 
each of the 21 TBI patients based on the mean and standard deviation of the group of 
the 11 healthy controls at each voxel. For comparison, z-score images were also 
computed for each healthy control versus the group of the remaining 10 healthy 
controls. The number of voxels with BPND z>1.645 (corresponding to P<0.05 1-
tailed) was used as a summary measure of the spatial extent of increased Flortaucipir 
signal for each participant. 
 
MRI lesion segmentation  
Structural MRI scans of all participants were reviewed by a senior 
neuroradiologist. Focal lesions apparent on T1 MRI were manually segmented in 
individual T1 space. Individual lesion maps were registered to MNI152 standard 
space using affine linear registration in FSL (58) and a 4mm FWHM Gaussian 
smoothing kernel was applied to these spatially normalised lesion maps to account for 
partial volume effects when applying the lesion maps to PET images. In individuals 
with focal lesions, BPND within lesions was compared to BPND in the rest of the 
cerebrum, excluding the striatum (where off-target binding was observed). Individual 
subjects’ lesions were excluded from voxelwise permutation analyses by 
incorporating a tool which uses voxels corresponding to individual lesions as 
voxelwise regressors in the general linear model (GLM).  
 
MRI processing 
Voxel-based morphometry was performed on volumetric T1 MRI images 
(59). T1 images were segmented into grey and white matter using SPM12 (55), and 
warped to an average group template using the diffeomorphic nonlinear registration 
(DARTEL) algorithm (56) then the individual flow-fields and template 
transformation from DARTEL were applied to produce MNI space images. No 
modulation was applied after spatial normalisation, therefore the resulting spatial 
maps represent tissue concentration (grey or white matter density), rather than 
volume (59, 60). Normalized grey and white matter density maps were spatially 
smoothed (8mm full width at half maximum (FWHM) Gaussian kernel).  
Diffusion-weighted images were preprocessed using standard methods (61) 
and tensor-based registration performed using DTI-TK (62). Fractional anisotropy 
(FA) maps were generated and registered for group analyses using tract-based spatial 
statistics (TBSS) (63). 
 
Statistical analyses 
Statistical analyses were carried out in the R statistical software (www.r-
project.org) (64) unless specified otherwise. Deviation from normal distribution was 
examined for all variables using the Shapiro-Wilk test and Q-Q plots. Two-tailed t-
tests and Mann-Whitney tests were used for between-group comparisons, as 
appropriate.  
Voxelwise differences in BPND between TBI participants and healthy controls, 
between each of the disabled TBI and good recovery TBI subgroups and healthy 
controls as well as between these subgroups were assessed using permutation tests in 
FSL (65). The same procedure was used to assess voxelwise differences between 
patients and controls in: i) VBM-derived white matter density ii) grey matter density 
and iii) diffusion MRI-derived skeletonised fractional anisotropy (FA). Voxels 
corresponding to structural lesions were excluded from the analyses by using 
subjects’ lesion maps as individual voxelwise repressors. All cerebral grey and white 
matter voxels were included except those corresponding to the striatum, where there 
is known off-target binding (13). 1000 permutations were used and results were 
cluster-corrected for multiple comparisons using threshold-free cluster enhancement 
(TFCE) and a family-wise error rate of 0.05. Localisation of significant voxel clusters 
was reported based on the Harvard-Oxford probabilistic atlas (66) and the JHU DTI-
based white matter atlas (67). 
To investigate whether white matter tau pathology shared common 
localisation with traumatic axonal injury and / or white matter atrophy in TBI, we 
compared skeletonized FA and, separately, average white matter density (z-scores) 
within areas of high Flortaucipir signal (BPND z>1.645) versus white matter areas 
where binding was not increased (BPND z<1.645) using (paired) Wilcoxon signed-
rank tests. Any voxels corresponding to focal lesions were excluded. Only TBI 
participants with 15 or more white matter voxels with increased Flortaucipir binding 
within the regions of interest were included.  
To examine the localisation of white matter microstructural damage predicted 
by increased Flortaucipir cortical signal in TBI participants, standardized BPND 
within the right parietal cortical area of significant Flortaucipir increase in TBI was 
used as a regressor in a voxelwise GLM of skeletonised FA, and separately, in a 
voxelwise GLM of white matter density. Statistical significance was tested using 
permutation tests in FSL (65). As previously, voxels corresponding to lesions were 
excluded for each individual, 1000 permutations were used and results were obtained 
using TFCE, corrected for multiple comparisons using a family-wise error rate of 
0.05. Localisation of significant voxel clusters was reported based on the JHU DTI-
based white matter atlas (67). Post-hoc correlations were examined using Spearman’s 
rank correlation between standardized BPND within the right parietal cortical area of 
significant Flortaucipir increase in TBI participants and skeletonized FA in the 
following tracts: right and left superior longitudinal, inferior longitudinal, inferior 
fronto-occipital fasiculi and cingulum bundles, corpus callosum (genu, body and 
splenium) as well as in the right and left corticospinal tracts as a control.   
Correlations between clinical/neuropsychological measures and PET markers 
in TBI participants were examined using Spearman’s rank correlation with false 
discovery rate (FDR) correction for multiple comparisons. Interactions between 
ApoE and age were assessed by comparing two linear regression models, with and 
without the interaction term, using chi squared test. Assumptions of multiple linear 
regression analysis were tested as follows: analysis of standard residuals was carried 
out to identify outliers; variance inflation factor was used to test for multicollinearity; 
Durbin-Watson test was conducted to test for independence of errors; approximate 
normal distribution of errors, homoscedacity and linearity were assessed by plotting 
regression standardized residuals. 
 
Supplementary Materials 
Fig. S1. Focal lesions in TBI participants. 
Table S1. Correlations between Flortaucipir right parietal cluster (TBI>Control) 
BPND (z-score compared to healthy controls) and FA in white matter tracts in TBI 
patients. 
Table S2. Correlations between clinical measures and each of: Flortaucipir right 
parietal cluster (TBI>Control) BPND, whole cerebral cortex BPND (z-score compared 
to the healthy control group), white matter BPND (z-score compared to the healthy 
control group) and spatial extent (N of voxels with BPND z-score>1.645 of healthy 
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Fig. S1: Focal lesions in TBI participants. Axial MRI slices of focal lesions (radiological 
convention). Patient labels correspond to those in Table 1 and Fig. 1-2. Participants P13 and 
P14 are not included as they did not have a focal lesion.  
 
 
White matter tract FA 
 
Right parietal ROI Flortaucipir 
BPND z-score 
 ρ P 
Cingulum bundle Right -0.68 <0.001 
Left -0.37 0.10 
Inferior longitudinal fasciculus Right -0.44 0.049 
Left -0.27 0.23 
Inferior fronto-occipital fasciculus Right -0.41 0.067 
Left -0.36 0.11 
Superior longitudinal fasciculus Right -0.20 0.38 
Left -0.06 0.79 
Anterior thalamic radiation 
 
Right -0.54 0.011 
Left -0.26 0.24 
Uncinate fasciculus Right -0.47 0.033 
 Left -0.04 0.85 
Corpus callosum 
 
Genu -0.68 <0.001 
Body -0.44 0.047 
Splenium -0.31 0.17 
Corticospinal tract Right -0.01 0.96 
Left -0.29 0.21 
 
Table S1: Correlations between Flortaucipir right parietal cluster (TBI>Control) BPND 
(z-score compared to healthy controls) and FA in white matter tracts in TBI patients. 







R parietal ROI 
Flortaucipir 
BPND z-score 
Grey matter Flortaucipir 
BPND z-score 




 ρ P ρ P ρ P ρ P 
Age (years)  -0.15 0.53 0.01 0.96 -0.11 0.65 0.11 0.62 
Time since injury 
(years) 
 0.15 0.52 -0.02 0.94 -0.01 0.95 0.18 0.44 
Disability GOS-E (current) -0.40 0.072 -0.02 0.92 -0.15 0.52 -0.33 0.15 
GOS-E (change) -0.25 0.37 -0.28 0.31 -0.47 0.075 -0.19 0.50 
Cognitive impairment MMSE (current) -0.32 0.16 -0.06 0.81 -0.04 0.85 -0.18 0.43 
MMSE (change) -0.34 0.24 -0.31 0.28 -015 0.62 -0.29 0.31 
Logical reasoning WASI Matrix Reasoning  -0.50 0.019 -0.01 0.96 -0.01 0.96 -0.22 0.33 
Processing speed 
 
Trail Making Test A  0.22 0.36 0.11 0.64 0.12 0.61 0.33 0.16 
Trail Making Test B  0.23 0.33 0.11 0.64 0.13 0.56 0.42 0.06
8 
Stroop Combined Baseline  -0.08 0.74 -0.05 0.81 0.02 0.93 -0.08 0.72 
CRT RT  0.50 0.024 0.29 0.19 0.25 0.28 0.51 0.01
7 
Executive function Trail Making Test B-A  0.13 0.59 0.08 0.73 0.10 0.67 0.37 0.11 
Stroop Inhibition-Switch 0.21 0.37 -0.009 0.97 0.009 0.97 0.17 0.47 
Stroop Inhibition-Switch 
vs Baseline  
0.04 0.87 -0.22 0.34 -0.20 0.39 -0.01 0.96 
FrSBe-Executive; current 0.06 0.81 -0.002 0.99 0.08 0.72 0.19 0.41 
Apathy  LARS  0.14 0.55 -0.07 0.77 -0.005 0.98 0.23 0.33 
FrSBe-Apathy; current 0.06 0.80 -0.07 0.76 -0.008 0.97 0.26 0.25 
Impulsivity / 
Disinhibition 
BIS  0.31 0.19 -0.09 0.70 0 1 0.06 0.81 
FrSBe-Disinhibition; 
current 
0.19 0.41 0.14 0.53 0.23 0.31 0.26 0.26 
Verbal memory DaPT People Immediate 
Recall  
-0.23 0.28 -0.05 0.81 0.02 0.94 -0.03 0.91 
DaPT People Delayed 
Recall 
-0.33 0.15 -0.04 0.86 0.06 0.81 0.06 0.81 
HVLT Immediate Recall  -0.23 0.32 -0.13 0.58 -0.15 0.51 -0.24 0.29 
HVLT Delayed Recall -0.27 0.24 -0.23 0.32 -0.20 0.39 -0.30 0.19 
HVLT RDI -0.31 0.17 -0.27 0.23 -0.20 0.39 -0.35 0.12 
Visual memory Paired Associates Learning  -0.13 0.58 0.06 0.79 -0.02 0.93 -0.13 0.58 
STMBT Binding Accuracy -0.38 0.16 -0.14 0.62 -0.19 0.50 -0.28 0.32 
BVMT Immediate Recall  -0.37 0.10 0.003 0.99 -0.08 0.72 -0.19 0.41 
BVMT Delayed Recall -0.37 0.10 -0.11 0.63 -0.10 0.65 -0.24 0.30 
BVMT RDI -0.18 0.45 -0.02 0.94 -0.001 0.99 -0.21 0.36 
Visuospatial ability Feature match test  -0.34 0.14 0 1 -0.16 0.49 -0.21 0.35 
Mood disturbance HADS-Anxiety 0.38 0.091 0.01 0.96 0.09 0.70 0.18 0.44 
HADS-Depression 0.18 0.44 -0.21 0.36 -0.17 0.47 0.14 0.53 
Abbreviations: BIS = Barratt Impulsivity Scale; BVMT = Brief Visuospatial Memory Test; CRT = Choice reaction time; DaPT = Doors and People’s Test; 
FrSBe = Frontal Systems Behavior Scale; GOS-E = Glasgow Outcome Scale – Extended; HADS = Hospital Anxiety and Depression Score; HVLT = Hopkins 
Verbal Learning Test; LARS = Lille Apathy Rating Scale; MMSE = Mini-mental State Examination; ms = milliseconds; RDI = Recognition Discrimination 
Index; RT = Reaction time; s = seconds; SD = Standard deviation; STBMT = Short Term Memory Binding Test; WASI = Wechsler Abbreviated Scale for 
Intelligence; WTAR = Wechsler Test of Adult Reading. 
Table S2: Correlations between clinical measures and each of: Flortaucipir right parietal cluster (TBI>Control) BPND, whole cerebral 
cortex BPND (z-score compared to the healthy control group), white matter BPND (z-score compared to the healthy control group) and 
spatial extent (N of voxels with BPND z-score>1.645 of healthy controls) in TBI patients. Spearman ρ coefficients and uncorrected P-values 
(P<0.05 in bold) are presented; all P>0.05 following FDR adjustment for multiple comparisons.  
 
